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First of all, Dr. Iinuma is to be congratulated for
studying this population of patients. Patients with
mental disabilities represent one of the largest pop-
ulations in pediatric epilepsy. However, researchers
generally tend to either not address this population
as a special group, or to avoid such studies because
of the behavior difﬁculties and other challenges.
The differences in the frequency of monother-
apy in this study illustrate the difﬁculty in treating
these patients. While monotherapy was used in 60%
of the normally intelligent patients in this study,
only 12% of those with intellectual disabilities were
treated with single agents. The mean number of
antiepileptic drugs (AEDs) was 1.6 for the ﬁrst group
versus 2.94 for the disabled group. Regardless of the
seizure type, better overall control was attainable
in the normally intelligent versus the intellectually
disabled persons.
The incidence of adverse events was interesting,
with 21% of the normal group experiencing side ef-
fects, 28% of the disabled, and 24% overall. Usu-
ally, adverse events are reported in the mentally
disabled population at about 20–40%. This is due to
the excess of behavioral abnormalities seen with so
many of our current drugs.
Zonisamide appears to be an effective AED in
both normal and intellectually deﬁcient children.
No special adverse effects were worsened in the
intellectually challenged group. Overall, we need
more double-blind, placebo-controlled, or com-
parative studies to determine which patients will
respond most favorably to treatment. This study
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examined the responses of normal versus intellec-
tually disabled children. We also need to better
deﬁne the adverse effects proﬁle of infants ver-
sus older children. For example, will a 5-year-old
or 3-year-old mentally disabled child respond the
same way as a 20-year-old mentally disabled indi-
vidual? We currently do not know the answer.
For these special population groups, we also need
to better deﬁne very speciﬁc abnormalities, such as
behavior abnormalities, anorexia, weight loss, and
hypohidrosis in particular. We need a strategy to
handle these adverse effects. Will we reduce the
drug? Discontinue the drug? There must be an avail-
able answer when the drug is being used in children.
US development must progress quickly to make
zonisamide available to children, the mentally
retarded population, and those with myoclonic
syndromes of various types including progres-
sive myoclonic epilepsy. However, we must be
syndrome-speciﬁc in our recommendations. While
the experience may be very good in a particu-
lar type of myoclonic syndrome, it may not be as
beneﬁcial in some of the other syndromes.
The once- or twice-a-day dosing is also an ad-
vantage. The 25mg preparation is acceptable and
would be welcomed, especially if it were available
as a divisible or chewable tablet.
In conclusion, despite the introduction in the US
of felbamate, lamotrigine, topiramate, gabapentin,
levetiracetam and oxcarbazepine patients with pro-
gressive encephalopathic epilepsy still require ad-
ditional agents. The data presented in this paper
and others, certainly suggest that zonisamide may
play an active role in meeting that need.
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